Clinical characteristics of COVID-19-infected cancer patients, Isfahan, Iran.
COVID-19
Coronavirus
neoplasms
retrospective case study
severe clinical events
Journal
Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences
ISSN: 1735-1995
Titre abrégé: J Res Med Sci
Pays: India
ID NLM: 101235599
Informations de publication
Date de publication:
2022
2022
Historique:
received:
27
06
2021
revised:
03
11
2021
accepted:
09
08
2022
entrez:
10
11
2022
pubmed:
11
11
2022
medline:
11
11
2022
Statut:
epublish
Résumé
Cancer patients, as a highly vulnerable population, are receiving a great deal of attention in the current crisis of coronavirus 2019 (COVID-19). To date, shreds of evidence are not sufficient to the description of COVID-19 outcomes in patients with cancer. This study was performed to evaluate the demographic and clinical characteristics and subsequent outcomes of COVID-19 in cancer patients. A hospital-based study was conducted involving 66 cancer patients with a confirmed diagnosis of COVID-19 from January 15, 2020, to December 21, 2020, in Isfahan, Iran. The clinical information was collected by interview and medical records. The statistical analyses were performed to describe categorical variables as well as mean, standard deviation, median, and the interquartile range for quantitative variables. In our study, 66 cancer patients with confirmed COVID-19 (age: 17-97 years; 50% female) were included. Leukemia and bone marrow cancer with a frequency of 25.7% were the most common types of cancer among them. Cancer patients mostly complained of fever, cough and fatigue, and shortness of breath. Among 76.9% of patients discharged from the hospital with relative recovery, 23% died; the most common cause of death was acute respiratory distress syndrome. Age, gender, and type of cancer did not affect cancer mortality. COVID-19 had no potential effect to increase the risk of side effects of anticancer therapies. The results of our studies revealed that cancer is an important risk factor for the higher rate of mortality in patients with COVID-19. These findings could help physicians for the management, treatment, and supportive care of COVID-19 cancer patients.
Sections du résumé
Background
UNASSIGNED
Cancer patients, as a highly vulnerable population, are receiving a great deal of attention in the current crisis of coronavirus 2019 (COVID-19). To date, shreds of evidence are not sufficient to the description of COVID-19 outcomes in patients with cancer. This study was performed to evaluate the demographic and clinical characteristics and subsequent outcomes of COVID-19 in cancer patients.
Materials and Methods
UNASSIGNED
A hospital-based study was conducted involving 66 cancer patients with a confirmed diagnosis of COVID-19 from January 15, 2020, to December 21, 2020, in Isfahan, Iran. The clinical information was collected by interview and medical records. The statistical analyses were performed to describe categorical variables as well as mean, standard deviation, median, and the interquartile range for quantitative variables.
Results
UNASSIGNED
In our study, 66 cancer patients with confirmed COVID-19 (age: 17-97 years; 50% female) were included. Leukemia and bone marrow cancer with a frequency of 25.7% were the most common types of cancer among them. Cancer patients mostly complained of fever, cough and fatigue, and shortness of breath. Among 76.9% of patients discharged from the hospital with relative recovery, 23% died; the most common cause of death was acute respiratory distress syndrome. Age, gender, and type of cancer did not affect cancer mortality. COVID-19 had no potential effect to increase the risk of side effects of anticancer therapies.
Conclusion
UNASSIGNED
The results of our studies revealed that cancer is an important risk factor for the higher rate of mortality in patients with COVID-19. These findings could help physicians for the management, treatment, and supportive care of COVID-19 cancer patients.
Identifiants
pubmed: 36353349
doi: 10.4103/jrms.jrms_541_21
pii: JRMS-27-73
pmc: PMC9639711
doi:
Types de publication
Journal Article
Langues
eng
Pagination
73Informations de copyright
Copyright: © 2022 Journal of Research in Medical Sciences.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Med Oncol. 2020 Aug 7;37(9):80
pubmed: 32767203
JCO Glob Oncol. 2020 Jun;6:799-808
pubmed: 32511066
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
BMC Infect Dis. 2021 Feb 10;21(1):170
pubmed: 33568084
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
Am J Emerg Med. 2021 Oct;48:140-147
pubmed: 33895645
Cancer Biol Med. 2020 Aug 15;17(3):519-527
pubmed: 32944387
Cancers (Basel). 2020 Nov 24;12(12):
pubmed: 33255220
J Hematol Oncol. 2020 Oct 8;13(1):133
pubmed: 33032660
J Clin Virol. 2020 Jun;127:104378
pubmed: 32353762
Hematol Oncol Stem Cell Ther. 2020 Jul 30;:
pubmed: 32745466
Cancer Biol Med. 2021 Feb 15;18(1):298-307
pubmed: 33628602
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Indian J Med Res. 2020 Feb & Mar;151(2 & 3):140-145
pubmed: 32317411
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
JNCI Cancer Spectr. 2021 Feb 24;5(2):pkaa102
pubmed: 33875976
PLoS One. 2020 Nov 5;15(11):e0241537
pubmed: 33151983
J Clin Med. 2020 Jul 29;9(8):
pubmed: 32751400
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
Cancer Prev Res (Phila). 2020 Nov;13(11):889-892
pubmed: 32958589
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Breast Cancer Res. 2020 May 28;22(1):55
pubmed: 32460829